LON:DXRX Diaceutics Interim Earnings Report GBX 134.89 +0.39 (+0.29%) As of 06:29 AM Eastern ProfileEarnings HistoryForecast Diaceutics EPS ResultsActual EPS-GBX 2.84Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ADiaceutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADiaceutics Announcement DetailsQuarterInterimDate9/23/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Diaceutics Earnings HeadlinesDiaceutics Issues Shares Under Employee Incentive Schemes in Latest Block Listing UpdateApril 7, 2026 | tipranks.comDiaceutics Executes Routine Management Share Purchases Under Incentive Plan With No Change to Share CapitalApril 1, 2026 | tipranks.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.July 17 at 1:00 AM | InvestorPlace (Ad)Diaceutics Issues New Shares to Trust as PDMRs Participate in Incentive PlanFebruary 3, 2026 | tipranks.comDiaceutics PLC Expands Employee Share Incentive PlanNovember 28, 2025 | tipranks.comDiaceutics PLC Enhances Employee Engagement with Share Incentive PlanNovember 4, 2025 | tipranks.comSee More Diaceutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Diaceutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Diaceutics and other key companies, straight to your email. Email Address About DiaceuticsAt Diaceutics (LON:DXRX) we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.View Diaceutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Abbott Laboratories Stock Is Suddenly Winning Back Wall StreetRevving Up Returns: Big Banks Race Through the Rate PlateauWhy Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the TestAI’s Power Crunch Fuels a Pivot for These 2 Oilfield StocksToast’s Comeback Story Is Getting Harder for Wall Street to IgnoreWhy Conagra’s Dividend Cut Could Be the Best Thing for InvestorsWhich Storage Stock Is Best Positioned to Win the AI Memory War? Upcoming Earnings HDFC Bank (7/18/2026)ICICI Bank (7/18/2026)General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026)Capital One Financial (7/21/2026)Interactive Brokers Group (7/21/2026)Charles Schwab (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
